

REMARKS

The changes being made are simply editorial in nature and no question of new matter or questions of further search arise.

Entrance of this amendment is respectfully requested.

In the paragraph which was inserted at the beginning at the specification, the priority document "JP2002-324056" should correct be "JP2002-324076". See the DECLARATION AND POWER OF ATTORNEY as filed.

The claims are slightly amended as follows.

In claims 7-11, "a" is added before "pharmaceutically".

Further, in claim 9, the "," is stricken "and" is added to end the group.

Claim 13 is amended by adding "and" since it makes the claim clearer.

Claim 18 is amended to use proper Markush group terminology.

Claims 23 and 26 are amended to include "disease" language simply for clarity.


Claim 28 is canceled since new claim 41 is added. The species of claim 41 is the compound which was recited in claim 18 at page 16 of the AMENDMENT...1.116, left column, last compound, this compound being the same compound as recited in [Example 128] at page 42 of the specification, noting that the vertical line | or the \wedge , in both cases represent a 2,2-dimethylpropanamide group.

Claim 40 is amended because the undersigned erroneously amended claim 40 in the AMENDMENT...1.116. Claim 40 is essentially returned to its original form noting the "," is stricken.

If the Examiner has any questions, the Examiner is requested to contact the undersigned
by telephone at the later given telephone exchange.

Entry and consideration of this Amendment are respectfully requested.

Respectfully submitted,



Peter D. Olexy
Registration No. 24,513

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: June 11, 2009